MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/blood.2024027197

Медицинская библиотека · Blood · 2025

Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis.

Perales Miguel-Angel, Awan Farrukh T, Boumendil Ariane, Patel Jinalben, Castagna Luca, Angelucci Emanuele, Finel Herve, Kulagin Alexander, Glass Bertram, Corradini Paolo, Herrera Alex F, Blaise Didier, Kharfan-Dabaja Mohamed A, Halahleh Khalid, Ahmed Sairah, Martínez Carmen, Giebel Sebastian, Montoto Silvia, Jones Richard J, Ahmed Nausheen, Lynch Ryan C, De Lima Marcos J, Shadman Mazyar, Sauter Craig S, Ahn Kwang W, Hamadani Mehdi, Bazarbachi Ali, Sureda Anna

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

Checkpoint inhibitors (CPIs) have shown remarkable efficacy in Hodgkin lymphoma (HL), and are now used routinely. While allogeneic hematopoietic cell transplantation (allo-HCT) remains a curative option for HL, there are concerns prior CPIs may exacerbate post-allo-HCT complications, particularly graft-versus-host disease (GVHD), and lead to worse outcomes. Given the relative paucity of data, we performed a Center for International Blood and Marrow Transplant Research/European Society for Blood and Marrow Transplantation study to examine the impact of prior CPIs in allo-HCT. We included 2186 adult patients aged >18 years who received a first allo-HCT using a matched related, unrelated, or haploidentical donor from 2008 to 2023. Twenty-seven percent of patients received prior CPIs. GVHD prophylaxis was posttransplant cyclophosphamide (PTCy) in 55.8% of patients in the CPI cohort, and 35% in the non-CPI cohort. Median follow-up among survivors was longer for the non-CPI (39 months) than CPI cohort (16.5 months). In multivariate analysis, prior CPI exposure did not affect overall survival (OS) or nonrelapse mortality, but resulted in improved progression-free survival (non-CPI vs CPI hazard ratio [HR], 0.81; 0.67-0.98; P = .03) and lower relapse incidence (HR, 0.58; 0.45-0.76; P < 001). While grade 2 to 4 (HR, 1.26; 1.04-1.53; P = .02) and 3 to 4 (HR, 1.41; 1.04-1.92; P = .03) acute GVHD (aGVHD) were increased, differences in chronic GVHD (cGVHD) were not significant. PTCy-based GVHD prophylaxis resulted in improved OS, lower grade 2 to 4 aGVHD, and cGVHD in patients with prior CPI exposure. In summary, allo-HCT should still be considered a curative option for patients with HL in the era of CPIs.

Для цитирования: Perales Miguel-Angel, Awan Farrukh T, Boumendil Ariane, Patel Jinalben, Castagna Luca, Angelucci Emanuele, Finel Herve, Kulagin Alexander, Glass Bertram, Corradini Paolo, Herrera Alex F, Blaise Didier, Kharfan-Dabaja Mohamed A, Halahleh Khalid, Ahmed Sairah, Martínez Carmen, Giebel Sebastian, Montoto Silvia, Jones Richard J, Ahmed Nausheen, Lynch Ryan C, De Lima Marcos J, Shadman Mazyar, Sauter Craig S, Ahn Kwang W, Hamadani Mehdi, Bazarbachi Ali, Sureda Anna. Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis.. Blood. 2025. DOI: 10.1182/blood.2024027197.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.